Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-based digital pathology confirmed denifanstat's strong anti-fibrotic activity, especially in portal and peri-portal regions. Preclinical data also demonstrated FASN inhibitor's potential in reducing atherosclerosis, cholesterol, and inflammatory markers, suggesting broader cardiometabolic benefits.
Sagimet Biosciences ha presentato i dati della fase 2b per denifanstat, il suo inibitore della sintetasi degli acidi grassi (FASN), all'AASLD 2024. Il trial FASCINATE-2 ha mostrato un significativo miglioramento nella fibrosi epatica in pazienti con MASH ad alto rischio, in particolare nella popolazione F3, dove il 49% dei pazienti trattati con denifanstat ha mostrato miglioramenti rispetto al 13% del gruppo placebo. La patologia digitale basata su AI ha confermato la forte attività anti-fibrotica di denifanstat, specialmente nelle aree portale e peri-portale. I dati preclinici hanno anche dimostrato il potenziale dell'inibitore FASN nella riduzione dell'aterosclerosi, del colesterolo e dei marcatori infiammatori, suggerendo benefici cardiometabolici più ampi.
Sagimet Biosciences presentó datos de la fase 2b para denifanstat, su inhibidor de la sintasa de ácidos grasos (FASN), en AASLD 2024. El ensayo FASCINATE-2 mostró una mejora significativa en la fibrosis hepática en pacientes con MASH de alto riesgo, particularmente en la población F3, donde el 49% de los pacientes tratados con denifanstat mostró mejoras frente al 13% del placebo. La patología digital basada en IA confirmó la fuerte actividad antifibrótica de denifanstat, especialmente en las regiones portal y periportal. Los datos preclínicos también demostraron el potencial del inhibidor de FASN para reducir la aterosclerosis, el colesterol y los marcadores inflamatorios, sugiriendo beneficios cardiometabólicos más amplios.
사기멧 생명과학(Sagimet Biosciences)는 AASLD 2024에서 지방산 합성 효소(FASN) 억제제인 데니판스타트(denifanstat)의 2b상 데이터를 발표했습니다. FASCINATE-2 시험은 고위험 MASH 환자에서 간 섬유증이 유의미하게 개선되었음을 보여주었으며, 특히 F3 집단에서는 데니판스타트 치료를 받은 환자 중 49%가 개선을 보였고, 위약군은 13%의 개선율을 보였습니다. AI 기반 디지털 병리학은 데니판스타트의 강력한 항섬유화 활성을 확인하였으며, 특히 문맥 및 주변 문맥 영역에서 두드러졌습니다. 전임상 데이터는 또한 FASN 억제제가 동맥경화, 콜레스테롤 및 염증 표지를 감소시키는 데 잠재력이 있음을 보여주어 더 넓은 심혈관 대사 이점을 시사합니다.
Sagimet Biosciences a présenté des données de phase 2b pour denifanstat, son inhibiteur de la synthase des acides gras (FASN), à l'AASLD 2024. L'essai FASCINATE-2 a montré une amélioration significative de la fibrose hépatique chez des patients MASH à haut risque, en particulier dans la population F3, où 49 % des patients traités par denifanstat ont montré des améliorations contre 13 % pour le placebo. La pathologie numérique basée sur l'IA a confirmé la forte activité anti-fibrotique de denifanstat, notamment dans les régions portales et péri-portales. Les données précliniques ont également démontré le potentiel de l'inhibiteur FASN pour réduire l'athérosclérose, le cholestérol et les marqueurs inflammatoires, suggérant des bénéfices cardiométaboliques plus larges.
Sagimet Biosciences präsentierte Phase-2b-Daten für denifanstat, seinen Inhibitor der Fettsäuresynthase (FASN), auf der AASLD 2024. Die FASCINATE-2-Studie zeigte eine signifikante Verbesserung der Leberfibrose bei Hochrisiko-MASH-Patienten, insbesondere in der F3-Population, wo 49% der mit denifanstat behandelten Patienten eine Verbesserung zeigten, im Vergleich zu 13% bei Placebo. KI-basierte digitale Pathologie bestätigte die starke antifibrotische Aktivität von denifanstat, insbesondere in portalen und peri-portalen Bereichen. Präklinische Daten zeigten auch das Potenzial des FASN-Inhibitors zur Reduzierung von Arteriosklerose, Cholesterin und Entzündungsmarkern, was auf breitere kardiometabolische Vorteile hindeutet.
- 49% of F3 patients treated with denifanstat showed fibrosis improvement vs 13% placebo (p=0.0032)
- 42% improvement in GLP1 receptor agonist population vs 0% placebo (p=0.034)
- 40% improvement in Type 2 diabetes population vs 19% placebo (p=0.0382)
- AI-based analysis showed 62% fibrosis improvement in F3 patients vs 26% placebo (p=0.005)
- Preclinical data showed reduction in cholesterol, triglycerides, and inflammatory markers
- None.
Insights
The FASCINATE-2 Phase 2b trial results for denifanstat show significant clinical progress in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis). Key findings include:
- In F3 population:
49% response rate with denifanstat vs13% placebo - Strong efficacy in high-risk subgroups including type 2 diabetes patients (
40% vs19% ) - AI-based pathology confirmed improvements in fibrosis, particularly in portal regions
- Preclinical data suggests potential cardiovascular benefits
This data significantly strengthens denifanstat's clinical profile as it moves toward Phase 3 trials. The drug's ability to improve fibrosis in difficult-to-treat patients and its potential cardiovascular benefits could position it as a leading MASH treatment option.
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients
Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity
FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024®, November 15-19, 2024 in San Diego, California.
“Our presentations of data from the Phase 2b FASCINATE-2 study highlight denifanstat’s impact on liver fibrosis, particularly in difficult-to-treat subsets of MASH patients who are at the highest risk of disease progression,” said Dave Happel, Chief Executive Officer of Sagimet. “Using an AI-based digital pathology approach, we observed pronounced fibrosis reduction in the peri-portal and portal zones of the liver, which as part of composite scores have recently been shown to correlate with liver outcomes and mortality, that may not be captured using conventional histological scoring. Finally, our preclinical data in a mouse model of MASH and dyslipidemia treated with a FASN inhibitor that is a surrogate for denifanstat showed that a FASN inhibitor may reduce circulating cholesterol and atherosclerosis development. Together, these results demonstrate the anti-fibrotic effects and potential cardiometabolic benefits of FASN inhibition and support the advancement of denifanstat into Phase 3 development.”
A poster titled “Denifanstat significantly improves liver fibrosis in difficult-to-treat MASH patients – Results from conventional and AI-based pathology from the phase 2b FASCINATE-2, a 52-week randomized, double-blind, placebo-controlled trial,” was presented by Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, the primary investigator of the FASCINATE-2 trial. Denifanstat treatment improved fibrosis by ≥ 1 stage without worsening of MASH in the higher-risk patient subgroups described below. Observed improvements by conventional pathology reading included:
- F3 population:
49% denifanstat (n=47) vs13% placebo (n=23) (p=0.0032) - GLP1 receptor agonist population:
42% denifanstat (n=12) vs0% placebo (n=4) (p=0.034) - Type 2 diabetes population:
40% denifanstat (n=55) vs19% placebo (n=27) (p=0.0382) - PNPLA3 I148 carrier population:
30% denifanstat (n=33) vs6% placebo (n=17) (p=0.022)
Strong consistency in fibrosis improvement was observed between conventional and AI-based pathology in the F3 population. Denifanstat treatment improved fibrosis by ≥ 1 stage in more than
- AI-based:
62% denifanstat (n=47) and26% placebo (n=23) (p=0.005) - Conventional:
55% denifanstat (n=47) and26% placebo (n=23) (p=0.021)
An oral presentation titled “AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis – results of the FASCINATE-2 study,” was presented by Mary Rinella, M.D. (University of Chicago). In this analysis, second harmonic generation (SHG) microscopy AI-based digital pathology was used to evaluate pre- and post-treatment liver biopsies. Denifanstat showed statistically significant liver fibrosis improvement, particularly in the portal and peri-portal regions. Improvement was observed with AI-based digital pathology not only in patients with >1-stage fibrosis improvement but also in patients with “no change” in fibrosis stage by conventional reading, representing important mechanistic insights provided by the AI-based platform. Select fibrosis parameters in the periportal and portal regions are part of AI-based composite score that have been recently linked to liver outcomes and mortality. Overall, both AI and conventional pathology readings demonstrated denifanstat's strong anti-fibrotic activity in MASH patients, including those with high risk of progression. These data reflect the unique mechanism of action of denifanstat and support the initiation of phase 3 trials.
Lastly, a poster titled “Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH,” was presented by Wen-Wei Tsai, Ph.D. (Sagimet Biosciences). In this mouse model, treatment with a FASN inhibitor that is a preclinical surrogate for denifanstat rapidly reduced circulating cholesterol, triglycerides and inflammatory markers associated with atherosclerosis, including CCL4 and CXCL2. The FASN inhibitor also reduced total atherosclerotic lesion area in the aortic root and improved liver steatosis, inflammation and fibrosis. These preclinical results suggest that a FASN inhibitor such as denifanstat could potentially provide benefits in cardiovascular as well as liver health, supporting the clinical evaluation of denifanstat for long term outcomes in MASH patients.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com.
About MASH
Metabolic dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and to improve diagnostic clarity.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What were the Phase 2b FASCINATE-2 trial results for denifanstat (SGMT) in F3 MASH patients?
How did denifanstat (SGMT) perform in diabetic MASH patients during the FASCINATE-2 trial?
What cardiovascular benefits did FASN inhibitor show in Sagimet's (SGMT) preclinical studies?
